As Ptc Therapeutics (Call) (PTCT) Shares Declined, Great Point Partners Lifted by $4.00 Million Its Position; As Bristol (BMY) Shares Declined, West Oak Capital Increased by $388,395 Its Position

January 14, 2018 - By Louis Casey

West Oak Capital Llc increased its stake in Bristol (BMY) by 149.45% based on its latest 2017Q3 regulatory filing with the SEC. West Oak Capital Llc bought 6,165 shares as the company’s stock declined 1.04% while stock markets rallied. The institutional investor held 10,290 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $655,000, up from 4,125 at the end of the previous reported quarter. West Oak Capital Llc who had been investing in Bristol for a number of months, seems to be bullish on the $102.80B market cap company. The stock increased 0.54% or $0.34 during the last trading session, reaching $62.81. About 5.49 million shares traded or 2.42% up from the average. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since January 14, 2017 and is downtrending. It has underperformed by 39.89% the S&P500.

Jeffrey Jay increased its stake in Ptc Therapeutics Inc (Call) (PTCT) by 76.92% based on its latest 2017Q3 regulatory filing with the SEC. Great Point Partners Llc bought 200,000 shares as the company’s stock declined 3.95% while stock markets rallied. The hedge fund run by Jeffrey Jay held 460,000 shares of the health care company at the end of 2017Q3, valued at $9.21 million, up from 260,000 at the end of the previous reported quarter. Great Point Partners Llc who had been investing in Ptc Therapeutics Inc (Call) for a number of months, seems to be bullish on the $966.29M market cap company. The stock increased 7.28% or $1.58 during the last trading session, reaching $23.29. About 1.30M shares traded or 33.60% up from the average. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 104.51% since January 14, 2017 and is uptrending. It has outperformed by 87.81% the S&P500.

Since January 3, 2018, it had 0 buys, and 4 selling transactions for $61,523 activity. $12,675 worth of PTC Therapeutics, Inc. (NASDAQ:PTCT) was sold by Almstead Neil Gregory on Friday, January 5. The insider Peltz Stuart Walter sold $40,207.

Investors sentiment increased to 1.71 in Q3 2017. Its up 0.79, from 0.92 in 2017Q2. It improved, as 13 investors sold PTCT shares while 28 reduced holdings. 25 funds opened positions while 45 raised stakes. 32.89 million shares or 5.85% more from 31.07 million shares in 2017Q2 were reported. Tudor Invest Et Al reported 19,270 shares. Ghost Tree Ltd stated it has 100,000 shares. Hanseatic Management holds 0% or 105 shares in its portfolio. Citigroup Inc stated it has 40,468 shares. Pub Employees Retirement System Of Ohio holds 0% or 11,582 shares in its portfolio. Nationwide Fund Advsrs invested in 21,718 shares or 0% of the stock. Matarin Cap Management Ltd Liability Com has 0.32% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 187,073 shares. Bogle Inv Ltd Partnership De holds 556,809 shares. Geode Limited Liability owns 363,005 shares for 0% of their portfolio. Alps holds 0.01% in PTC Therapeutics, Inc. (NASDAQ:PTCT) or 40,762 shares. New York-based Consonance Mngmt Lp has invested 8.73% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Bnp Paribas Arbitrage invested in 0% or 3,991 shares. Goldman Sachs Group Inc Incorporated Inc reported 282,450 shares or 0% of all its holdings. Janney Montgomery Scott Ltd owns 27,827 shares. Oppenheimer And Communication holds 15,093 shares.

Among 12 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 1 Sell and 7 Hold. Therefore 33% are positive. PTC Therapeutics had 34 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was maintained by Wedbush on Wednesday, February 24 with “Outperform”. Citigroup downgraded the stock to “Neutral” rating in Wednesday, February 24 report. The firm has “Sell” rating by Bank of America given on Thursday, October 26. As per Monday, October 9, the company rating was downgraded by J.P. Morgan. The stock has “Underperform” rating by Jefferies on Wednesday, November 25. The firm has “Sector Perform” rating by RBC Capital Markets given on Friday, November 11. On Thursday, November 16 the stock rating was upgraded by JP Morgan to “Neutral”. The rating was downgraded by Credit Suisse on Tuesday, July 26 to “Neutral”. The firm has “Hold” rating given on Thursday, September 14 by RBC Capital Markets. The stock has “Buy” rating by Citigroup on Friday, November 11.

Great Point Partners Llc, which manages about $935.83 million and $514.03M US Long portfolio, decreased its stake in Zogenix Inc (Call) by 1.94 million shares to 500,000 shares, valued at $17.53M in 2017Q3, according to the filing. It also reduced its holding in Selecta Biosciences Inc by 35,653 shares in the quarter, leaving it with 901,847 shares, and cut its stake in Dbv Technologies Sa.

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.08, from 0.95 in 2017Q2. It is positive, as 62 investors sold BMY shares while 519 reduced holdings. 137 funds opened positions while 460 raised stakes. 1.11 billion shares or 0.68% more from 1.10 billion shares in 2017Q2 were reported. Grimes holds 8,111 shares or 0.05% of its portfolio. Hm Payson And invested in 89,048 shares or 0.24% of the stock. First State Bank And Tru Of Newtown stated it has 0.75% in Bristol-Myers Squibb Company (NYSE:BMY). Principal Grp holds 0.16% or 2.60M shares in its portfolio. Mcdaniel Terry holds 0.07% or 5,450 shares in its portfolio. Shine Advisory Ser holds 2,170 shares or 0.07% of its portfolio. Citizens And Northern Corp owns 26,372 shares. Mitsubishi Ufj Tru Bk owns 3.39 million shares. Colonial Trust Advsr reported 7,729 shares. 3,369 are held by Roosevelt Group. Sequoia Advisors Limited Liability Co owns 6,653 shares. Aviance Cap Partners holds 0.33% or 15,296 shares. Cibc has 0.09% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 296,341 shares. Envestnet Asset Mngmt Inc has 0.01% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 50,489 shares. Accredited Investors owns 15,055 shares for 0.26% of their portfolio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>